FDA Approves Baxter's Hemophilia B Drug Rixubis for Pediatric Use
Sunday, September 28, 2014
Source: BioSpectrum Asia
Baxter International has received the FDA's approval to market Rixubis, or coagulation factor IX (recombinant), for the treatment of children with hemophilia B. The drug was approved for use in routine prophylaxis, perioperative management and control of bleeding episodes.